Influenza and pneumococcal vaccine coverage among adults hospitalized with acute respiratory infection in France: A prospective cohort study

IF 4.3 2区 医学 Q1 INFECTIOUS DISEASES International Journal of Infectious Diseases Pub Date : 2025-04-01 Epub Date: 2025-02-03 DOI:10.1016/j.ijid.2025.107811
Simon Rolland , LB. Luong Nguyen , A. Descamps , F. Galtier , X. Duval , P. Vanhems , F. Lainé , P. Tattevin , R. Bauer , O. Launay , FLUVAC study group
{"title":"Influenza and pneumococcal vaccine coverage among adults hospitalized with acute respiratory infection in France: A prospective cohort study","authors":"Simon Rolland ,&nbsp;LB. Luong Nguyen ,&nbsp;A. Descamps ,&nbsp;F. Galtier ,&nbsp;X. Duval ,&nbsp;P. Vanhems ,&nbsp;F. Lainé ,&nbsp;P. Tattevin ,&nbsp;R. Bauer ,&nbsp;O. Launay ,&nbsp;FLUVAC study group","doi":"10.1016/j.ijid.2025.107811","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>This study aimed to estimate influenza and pneumococcal vaccination coverage among adults hospitalized with severe acute respiratory infections in France from 2016 to 2022 and to analyze factors associated with vaccination.</div></div><div><h3>Methods</h3><div>We analyzed data from a prospective multicenter study involving adults hospitalized with severe acute respiratory infections. Descriptive and comparative analyses of influenza and pneumococcal vaccination coverage were conducted along with multivariate logistic regression to identify the factors associated with vaccination.</div></div><div><h3>Results</h3><div>We included 4,614 patients; 88% (4,080/4,614) had an indication for influenza vaccination. Among them, 2,181/4,080 (53%) were vaccinated against influenza. Factors associated with vaccination included age ≥65 years (adjusted odds ratio [aOR] 3.05; 95% confidence interval [CI] 2.63-3.55) and chronic respiratory diseases (aOR 1.38; 95% CI 1.20-1.59). Pneumococcal vaccination status was available for 90% (4,142/4,614) of patients, of whom 71% (2,920/4,142) had an indication for vaccination. Pneumococcal vaccination coverage was 19% (551/2,920). The factors associated with vaccination were chronic respiratory disease (aOR 2.74; 95% CI 2.22-3.40) and immunocompromised conditions other than malignancies. The vaccination coverage for each vaccine did not increase over time. Among the 3,247 patients eligible for both vaccines, 13% received both vaccines.</div></div><div><h3>Conclusions</h3><div>In this high-risk population, the vaccination coverage was low, particularly with pneumococcal vaccines. Therefore, improved vaccination recommendation strategies and communication are required.</div></div>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":"153 ","pages":"Article 107811"},"PeriodicalIF":4.3000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1201971225000359","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/3 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives

This study aimed to estimate influenza and pneumococcal vaccination coverage among adults hospitalized with severe acute respiratory infections in France from 2016 to 2022 and to analyze factors associated with vaccination.

Methods

We analyzed data from a prospective multicenter study involving adults hospitalized with severe acute respiratory infections. Descriptive and comparative analyses of influenza and pneumococcal vaccination coverage were conducted along with multivariate logistic regression to identify the factors associated with vaccination.

Results

We included 4,614 patients; 88% (4,080/4,614) had an indication for influenza vaccination. Among them, 2,181/4,080 (53%) were vaccinated against influenza. Factors associated with vaccination included age ≥65 years (adjusted odds ratio [aOR] 3.05; 95% confidence interval [CI] 2.63-3.55) and chronic respiratory diseases (aOR 1.38; 95% CI 1.20-1.59). Pneumococcal vaccination status was available for 90% (4,142/4,614) of patients, of whom 71% (2,920/4,142) had an indication for vaccination. Pneumococcal vaccination coverage was 19% (551/2,920). The factors associated with vaccination were chronic respiratory disease (aOR 2.74; 95% CI 2.22-3.40) and immunocompromised conditions other than malignancies. The vaccination coverage for each vaccine did not increase over time. Among the 3,247 patients eligible for both vaccines, 13% received both vaccines.

Conclusions

In this high-risk population, the vaccination coverage was low, particularly with pneumococcal vaccines. Therefore, improved vaccination recommendation strategies and communication are required.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
法国急性呼吸道感染住院成人的流感和肺炎球菌疫苗覆盖率:一项前瞻性队列研究
目的:本研究旨在估计2016年至2022年法国因严重急性呼吸道感染(SARI)住院的成人流感和肺炎球菌疫苗接种覆盖率(VC),并分析与疫苗接种相关的因素。方法:我们分析了一项前瞻性多中心研究的数据,研究对象是住院的成人严重急性呼吸道感染。对流感和肺炎球菌风险进行了描述性和对比性分析,并进行了多变量logistic回归,以确定与疫苗接种相关的因素。结果:我们纳入了4614例患者;88%(4080/4614)有流感疫苗接种指征。其中,2181/4080(53%)接种了流感疫苗。与疫苗接种相关的因素包括年龄≥65岁(校正优势比[aOR] 3.05;95% CI 2.63 - 3.55),慢性呼吸系统疾病(aOR 1.38;95% ci 1.20 - 1.59)。90%(4142/4614)患者接种了肺炎球菌疫苗,其中71%(2920/4142)有接种指征。肺炎球菌VC为19%(551/2920)。与疫苗接种相关的因素是慢性呼吸道疾病(aOR 2.74;95% CI 2.22 - 3.40)和非恶性肿瘤的免疫功能低下。每种疫苗的VC没有随时间增加。在符合两种疫苗接种条件的3247名患者中,13%的人同时接种了两种疫苗。结论:在该高危人群中,VC较低,尤其是肺炎球菌疫苗。需要改进疫苗接种推荐策略和沟通。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
18.90
自引率
2.40%
发文量
1020
审稿时长
30 days
期刊介绍: International Journal of Infectious Diseases (IJID) Publisher: International Society for Infectious Diseases Publication Frequency: Monthly Type: Peer-reviewed, Open Access Scope: Publishes original clinical and laboratory-based research. Reports clinical trials, reviews, and some case reports. Focuses on epidemiology, clinical diagnosis, treatment, and control of infectious diseases. Emphasizes diseases common in under-resourced countries.
期刊最新文献
Inosine pranobex was associated with a reduction in mortality in COVID-19 by over 22%, as reported in a retrospective study utilizing complete health data from the Czech national registry. Inosine pranobex as a treatment of SARS-CoV2? The risk of transfusion-transmitted infection: First evidence of Oropouche virus detection in an asymptomatic blood donor in Southeastern Brazil Associations of human mobility patterns with dengue fever in China: A spatiotemporal modeling analysis from 2005 to 2023 Northern Hemisphere 2025/26 influenza vaccine effectiveness during months with influenza A(H3N2) subclade K predominance— Suzhou, Eastern China
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1